Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $35.31 USD
Change Today +0.45 / 1.29%
Volume 145.1K
VASC On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

vascular solutions inc (VASC) Snapshot

Open
$34.60
Previous Close
$34.86
Day High
$35.79
Day Low
$34.01
52 Week High
04/24/15 - $35.79
52 Week Low
05/20/14 - $18.42
Market Cap
609.6M
Average Volume 10 Days
172.4K
EPS TTM
$0.88
Shares Outstanding
17.3M
EX-Date
--
P/E TM
39.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for VASCULAR SOLUTIONS INC (VASC)

Related News

No related news articles were found.

vascular solutions inc (VASC) Related Businessweek News

No Related Businessweek News Found

vascular solutions inc (VASC) Details

Vascular Solutions, Inc., a medical device company, provides various solutions to interventional cardiologists, interventional radiologists, electro physiologists, and vein practices worldwide. The company’s catheter products include GuideLiner catheters for use in various interventions; Pronto extraction catheters for treating acute myocardial infarction; Micro-Introducers for performing arterial and venous catheterization procedures; Langston to measure intravascular pressure gradients for the diagnosis of aortic valve stenosis; and SmartNeedle, a doppler-guided needle device designed to provide auditory ultrasound-guided access to arteries and veins. It also offers Venture, a deflectable tip catheter used for steering guidewires in various interventions; Guardian, a hemostat valve to allow placement of multiple devices simultaneously; SuperCross, a catheter for support and delivery of guidewires during coronary and peripheral interventions; Snares to retrieve or manipulate devices in catheterization procedures; and Minnie, a support catheter used to facilitate placement and exchange of guidewires and other interventional devices. In addition, the company provides hemostat products comprising D-Stat Dry Thrombix, a thrombin-based hemostat bandage used in conjunction with manual compression to control bleeding in catheterizations; D-Stat Flowable, a flowable mixture to control bleeding in the pectoral pockets; Vasc Band, a compression device that utilizes an inflatable membrane to control bleeding; D-Stat Radial, a compression device that utilizes a thrombin pad to control bleeding; and accumed wrist positioning splint. Further, it offers vein products and services, such as Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, as well as a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The company was founded in 1996 and is headquartered in Minneapolis, Minnesota.

485 Employees
Last Reported Date: 02/3/15
Founded in 1996

vascular solutions inc (VASC) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $525.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $280.0K
Senior Vice President of Operations
Total Annual Compensation: $360.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $196.0K
Senior Vice President of International Sales
Total Annual Compensation: $285.0K
Compensation as of Fiscal Year 2014.

vascular solutions inc (VASC) Key Developments

Vascular Solutions Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015; Revises Earnings Guidance for the Year 2015

Vascular Solutions Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $34,611,000 compared to $29,907,000 a year ago. Operating earnings were $3,423,000 compared to $4,371,000 a year ago. Earnings before income taxes were $3,451,000 compared to $4,373,000 a year ago. Net earnings were $2,207,000 or $0.12 per diluted share compared to $2,799,000 or $0.16 per diluted share a year ago. Non-GAAP adjusted operating earnings were $5,856,000 or $0.21 per diluted share compared to $4,886,000 or $0.18 per diluted share a year ago. During the first quarter, the company generated $4.9 million in cash from operations, and the company used cash of $2.7 million to acquire an additional adjacent manufacturing facility, $2.7 million for capital expenditures related to building improvements and the purchase of manufacturing, computer, and research and development equipment. For the second quarter of 2015, the company is providing guidance for net revenue of between $35.5 million and $36.5 million, which at the mid-point represents growth of 17% from the second quarter of 2014. The company is providing adjusted net earnings guidance for the second quarter of 2015 of between $0.25 and $0.27 per fully diluted share. The company's adjusted net earnings guidance for the second quarter of 2015 includes $800,000 in non-cash stock-based compensation, $400,000 in amortization of intangibles, $400,000 for the U.S. medical device excise tax, and an assumed 35% effective income tax rate.   For the full year 2015, the company is raising its guidance for net revenue to a range of $140 million to $144 million. The mid-point of this range represents a 13% increase from net revenue of $126.1 million in 2014. The company's previous net revenue guidance range for 2015 was $139 million to $143 million. The company also is raising its adjusted earnings guidance for the full year 2015 to a range of $0.93-$0.97 per share. Previously, the company's 2015 adjusted EPS guidance was $0.88-$0.92. Included in the company's revised 2015 earnings guidance are $3.9 million in non-cash stock-based compensation, $1.6 million in amortization of intangibles, between $1.5 million and $1.7 million for the U.S. medical device excise tax, and an assumed 36% tax rate.

Vascular Solutions Inc. to Report Q1, 2015 Results on Apr 21, 2015

Vascular Solutions Inc. announced that they will report Q1, 2015 results at 3:30 PM, Central Standard Time on Apr 21, 2015

Vascular Solutions Inc., Q1 2015 Earnings Call, Apr 21, 2015

Vascular Solutions Inc., Q1 2015 Earnings Call, Apr 21, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASC:US $35.31 USD +0.45

VASC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.10 USD +0.25
CryoLife Inc $10.18 USD +0.05
LeMaitre Vascular Inc $8.60 USD +0.03
STAAR Surgical Co $9.14 USD +0.02
Stereotaxis Inc $2.15 USD -0.0901
View Industry Companies
 

Industry Analysis

VASC

Industry Average

Valuation VASC Industry Range
Price/Earnings 51.1x
Price/Sales 4.6x
Price/Book 5.2x
Price/Cash Flow 43.7x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR SOLUTIONS INC, please visit www.vascularsolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.